US based biotech firm Alnylam is to invest hundreds of millions of pounds in Britain to open its new European headquarters in Berkshire.
The US firm is set to hire a new team of more than 100 people in Maidenhead, in the latest sign the vote to leave the European Union is not deterring investment in Britain's businesses and economy.
Alnylam is a £5billion firm predominantly developing RNA interference (RNAi) technology, which seeks to understand how genes are turned on and off in cells.
Akshay Vaishnaw, chief medical officer at the biotech company, said: "We’re thrilled to be expanding our global presence in the United Kingdom and Maidenhead in particular.
"This important new office will play a critical role in advancing our cutting-edge investigational RNAi therapies toward regulatory approval and launch in European markets to benefit patients with life-threatening diseases as quickly as possible."
Brendan Martin, who will head the UK operation for the firm, added: "With its strong academic and clinical research sector, as well as its universal health service and regulatory bodies constantly striving to be more streamlined and efficient, the UK has a lot to offer as a development hub for innovative medicines.
"Our investment here signals a trust that the UK community will continue to treat this mission with the urgency and importance it deserves."
0 comments: